Current Surgical Patches and Novel Wound Closure Techniques
Kishan S. Gohil1*, Sahana A. Lakhawala1, Vipul P. Patel2
1Research Scholar, School of Pharmacy, RK University, Rajkot, Gujarat, India
2Associate Professor, School of Pharmacy, RK University, Rajkot, Gujarat, India
*Corresponding Author E-mail: kishangohil1994@gmail.com
ABSTRACT:
The alarming incidence of bacterial resistance even in regions with improved healthcare systems has accelerated the need to search for alternative antibacterial therapies. Considering this, hexane, ethanol, aqueous, methanol and chloroform leaf extract of Daturainoxiawerescreened for their antibacterial activity against the clinical strains of Staphylococcus aureus, Pseudomonas aeruginosa and Escherichia coli isolated from blood, urine and pus. Agar well diffusion assay was employed to detect inhibitory activity of the plant. Ethanolic extract was found most effective among all the tested extracts. The extract showed greater inhibitory activity against the strains of Staphylococcus aureus. Ethanolicextract was further subjected for fractionation through column chromatography. Different isolated fractions were again screened for their antibacterial activity against the strains of Staphylococcus aureus. All the fractions showed inhibitory activity, of which fraction 4 was found effective against all the tested strains. Present study also revealed that, both gram negative and gram positive bacterial isolates from urine samples were more inhibited by the ethanolic extract than the isolates from pus and blood samples. Further studies are needed to explore theantibacterial activity of this ethanolic extract in various urinary tract infections, which presently require long term treatment with synthetic antibiotics.
KEYWORDS: Surgical Patches, Novel Wound Closure Techniques, Innovative Wound Closure, Transdermal Drug Delivery System, Current Wound Closure Techniques.
INTRODUCTION:
Currently most of the surgeries ends with stitches or staples type modern technology for wound closures. Staples and stitches are painful either on application or at a time of removal as it usually require surgical removal although used as indicated clinically. It has so poor patient compliance majorly in pediatrics and also in geriatrics patients some times. It also requires care and protection after treatment. There are number of complications in traditional and current wound closure technology like wound infections, excessive scarring, keloid formation etc. In some cases wound reopening are also observed and it fails to give fluid tight closures. Nowadays medical science technology are at the top of innovative stage to increase patient compliance and to give better post treatment effect by reducing such type of complications.
Go Pain BioFuse Patches are exclusive innovative patches that prevents the use of stitches, staples, clips, strips etc. It is easy to apply and remove without any pain. It also contains transdermal drug delivery system. [1]
Commonly oral route for the drug delivery are most popular among all. However it have number of drawbacks like drug degradation in GIT, first pass metabolism, pH etc. To resolve this transdermal drug delivery system was developed. This novel drug delivery system is in combination with surgical patch, which is applied over the wound or incision and gives drug delivery action to that local area. It locally gives anesthetic effect to reduce the pain. It gives predetermined therapeutic effect over a prolonged period of time. This is adhesive type patches that act as both device and treatment.
In transdermal system drugs are mixed with specific polymer like natural, synthetic and synthetic elastomer which will provide the drug release in controlled manner. Patch have high concentration of drug and skin have low concentration or drug is absent in the systemic circulation. Hence drug shows passive diffusion from the dosage form to the systemic circulation through the skin. It keep on diffusing until the concentration reaches equilibrium phase, so due to this change in concentration it gives prolong duration of action.[2]
First transdermal patch which was approved by the FDA was Transdermal Scopolamine Patch used for nausea and motion sickness in1979. Patch was for three day that deliver scopolamine drug. After 1981 numbers of patches are developed in market for the drugs like lidocaine, nitroglycerin, nicotine, estradiol etc. Nanoemulsion, nanoparticles, nano gels are an attempt to formulate the transdermal drug delivery system for many drugs.[3,4]
Types of Transdermal drug delivery system
1. Drug in adhesive type
2. Multi-layer type
3. Reservoir type
4. Matrix type
There are 3 most common pathways for drugs to get penetrate through the skin which are
· Through the sweat ducts,
· Through the hair follicles and glands,
· Directly across the stratum corneum.
Hence TDDS have much more advantages compare to oral route. Instead of this it also have great patient compliance because it gives prolong duration of action by controlled release mechanism and also reduces the frequent administration.
This is basic theoretical aspects regarding the transdermal drug delivery system which is necessary to discuss before going for any novel transdermal related project. [5–7]
1. Current Wound Closure Technique:
At present there are mainly three types of basic ways for wound closing which are
1. Primary Closure - It works faster among all type of closure, and also heals by primary intentions. Wounds which are small clean defect that is less risky of infection and require to travel only a small distance for blood vessels to heal by this closure. These types of wounds are not trouble for wound care specialist.
2. Secondary Closure - It heals the wound in which both wound edges can’t be accurate. A granulation tissue matrix is required to fill the wound defect. These closures are more time and energy consuming than primary closure. Most of the wounds are treated by this closure.
3. Delayed Primary Closure - Occasionally, wounds are closed by delayed primary closure, also known as healing by tertiary intention. Delayed primary closure is a combination of healing by primary and secondary intention and is usually instigated by the wound care specialist to reduce the risk of infection. In delayed primary closure, the wound is first cleaned and observed for a few days to ensure no infection is apparent, before it is surgically closed. Examples of wounds that are closed in this way include traumatic injuries such as dog bites or lacerations involving foreign bodies.
For Example:-Sutures, Surgical Staples and Surgical Skin Tapes[8]
2. Introduction to Patch
Currently TDDS are frequently used in the medical treatment as it has number of benefits and great patient compliance. Hence in market there are many Transdermal patches available that requires different components to formulate it which is described below.
Basic Components for TDDS:[9–11]
· Release Liner.
· Polymer Matrix / Drug reservoir.
· Pressure Sensitive Adhesive. (PSA)
· Backing Laminates.
· Permeation Enhancers.
· Drugs.
· Other Excipients like Plasticizers and Solvents.
1. Release Liner: [9–11]
Release liner is the outer part of the patch which is made up of Silicone/Teflon or Occlusive - Polyethylene, PVCor Non Occlusive - Paper Fabric.
Drugs are protected by this type of release liner from the outer environment. Release liner is easily peelable at the time of application. It covers the adhesive layer of the patch during the storage. It doesn’t interact with any drugs or polymer or adhesive.
2. Polymers: [9–11]
It acts as a backbone for the TDDS. Patches are fabricated as a multi layered polymeric laminates. Drugs are mixed with polymers and adhesive material to make patch more effective. Polymers help to release the drug in controlled manner from the patch. Polymers are also compatible with drugs and helps in diffusion. There are main 3 types of polymers
· Natural Polymers
· Synthetic Polymers
· Semi Synthetic Polymers
Natural Polymers Used is
§ Cellulose derivatives,
§ Chitosan,
§ Waxes,
§ Gums,
§ Shellac,
§ Zein,
§ Natural Rubber,
§ Gelatin, etc.
Synthetic Elastomer Used is
§ Butyl Rubber,
§ Hydrin Rubber,
§ Silicon Rubber,
§ Polybutadiene,
§ Polyisobutylene,
§ Acrylonitrile,
§ Nitrile,
§ Neoprene, etc.
Synthetic Polymers Used is
§ Polyvinylpyrrolidone,
§ Polyvinylchloride,
§ Polyvinyl Alcohol,
§ Polypropylene,
§ Polyethylene,
§ Polyacrylate,
§ Polyurea,
§ Polymethylmethacrylate,
§ Polyamide etc.
Other Rate Controlling Polymers is
§ Silicon Rubber,
§ Polyurethane,
§ EVA.
3. Matrix Formers: [9–11]
The polymers like cross linked polyethylene glycol, polyvinylpyrrolidone, ethyl cellulose, hydroxypropylmethylcellulose, and eudragits are used as matrix formers. It forms matrix like structure and entrapped the drug molecules into that structure and hence gives controlled drug release.
4. Adhesive Materials:[9–11]
Adhesive materials are used to stick the patch on to the skin surface. It helps the patch to retain over the skin surface. It contains strong adhesive properties which retain over the skin even on wear and tear. It also holds with skin in moisture environment. Release Liner covers this layer prior to the administration.
5. Backing Layer:[9–11]
Baking Layer is outer layer of the patch which acts as ventilation and provides the oxygen supply to the affected area. It prevents the diffusion of drug from the upper layer and provides the unidirectional diffusion system. It also acts as a reservoir for the drugs in certain patches. Drugs get stored in this layer and diffuse out over a predetermined time period.
6. Drugs:
The Drug should posses the right pharmacokinetic and physicochemical properties. It should hydrophilic as well as lipophilic in nature with low melting point. It should be non irritant in nature. Drugswith narrow therapeutic window or drugs with short half life are suitable. It overcomes the problem with drugs which undergo extensive first pass metabolism, degrading in GI Tract etc due to this frequent dosing is required which leads to non compliance.[9–12]
For example, drugs like Lidocaine as local anesthetic, rotigotine for parkinson, scopolamine for motion sickness, rivastigmine for alzheimer’s and parkinson dementia, methylphenidate for attention deficit hyperactive disorder and selegiline for depression are recently approved as TDDS.[3,4]
Table No. 1 Different Polymers of Patches
|
Polymers |
Remarks |
|
Natural / Synthetic Polymers[2,13,14] |
|
|
Natural Rubber[2,13,14] |
Viscoelastic material can also term as rubber which have properties of pressure sensitive adhesive. Rubber which is suitable includes polyisobutylene, polysiloxane, and natural rubber. |
|
It isan addition polymer and milky white fluid which is obtained aslatex from a tropical rubber tree. It is from the monomer isoprene (2-methyl-1, 3 butadiene). |
|
|
Chitosan [2,13,14] |
It is highly basic polysaccharides then other natural polymers. It consists of unique properties like polyoxysalt formation, ability to form films, and highly hydrophobic. It has application in controlled drug release formulations due to its gel forming ability. |
|
Zein[2,13,14] |
It has no considerable attention as a alternative for film forming agents. It is available as inexpensive and most effective for fast disintegrating synthetic and semi synthetic film coatings. |
|
Gelatin Cellulose Derivative[2,13,14] |
It would control the rate of diffusion of the penetration enhancer and applicable as an adhesive layer when used in dermatology. |
|
Natural Gums and Mucilage[15] |
These polymers are preferred as excipients because of its lack of toxicity, low cost, availability, non-irritant nature and biocompatible. |
|
Xanthan Gums[2,16] |
It acts as a stabilizer, thickener and emulsifier It is selected with ethyl cellulose as a backing layer of patch. |
|
Shellac[2] |
It is chemically similar to synthetic polymer although it is natural polymer. It considered as a natural form of plastic. |
|
Neoprene and Butyl Rubber[17] |
It is best material for fabricating polymer layer which is biologically acceptable. |
|
Polytetrafluoroethylene (PTFE)[18] |
Patch using PTFE polymer shows that there is no a technical problem or adverse effects associated with it. |
|
Polyvinylpyrrolidone[19] |
It will act as a crystallization inhibitor or solubility enhancer. |
|
β-cyclodextrin [16] |
It shows acceptable uniform thickness, weight, content, stability and also enhances solubility when form complexes withβ-cyclodextrin. |
|
Eudragits L100[20,21] |
It is effective as crystallization inhibitor and gives transparent system with good film properties with high skin permeation. |
Table No. 2 Different Excipientsused in Patches
|
Excipients/Vehicles/Adhesive |
Remarks |
|
Release Liner[22,23] |
|
|
Non Occlusive - Paper Fabric |
It is observed that film, a paper or a laminate which are made up of polyethylene, polyester, polyvinylchloride etc. and coated with silicone resin or fluoride resin are used. It is made up of Drug / Vehicle impermeable matrial which protects the patch during storage and drug remain safe within it. |
|
Occlusive - Polyethylene, PVC |
|
|
Release Coating Layer – Silicone/Teflone |
|
|
Plasticizers [21,24,25] |
|
|
Glycol Derivatives |
It improves the film forming properties, increases flexibility, and give controlled rate of drug release. |
|
Glycerol / Sorbitol |
It makes patch more elastic and pliable |
|
Baking Laminate [5,10,21,26] |
|
|
Polyethylene Film Polyester Film Aluminum Coated Film Polyolefin Film |
It should be flexible and having low water vapour transmission rate so that it can promote the skin permeation. It must be non irritant and compatible. Its primary function is to support the patch. |
|
Pressure Sensitive Adhesive[27–30] |
|
|
Polyisobutylene Based Adhesive Acrylics and Silicon Based Polymers |
Polymers are used to give Controlled release rate of the drug and enhance the penetration. Release rate can be controlled by varying the polymer composition, thickness and the type of adhesive. |
|
Solvents[10,31] |
|
|
Water Alcohol Alkyl Methyl Sulfoxide Azone |
Compounds that increases the penetration by swelling. It includes the solvents like methanol, ethanol, propylene glycol, glycerol, silicon fluids etc. It also provides plasticity to the patch. |
Table No. 3 Current Surgical Wound Closure Technique
|
Surgical Patch and Wound Closure |
Marketed Product Name |
Remarks |
|
Topical SkinAdhesive[32,33] |
Tegaderm
|
Mostly used to treat wound topically by using the transparent and strong adhesive patch which helps to close wound and permits the wound for observation. |
|
Adhesive Skin Closure[34] |
3M Steri Strip |
It is a plastic fabric material with protective film and adhesive baking layer applies to an incision or wound which gets close by stretching the edges of wounds after Appling strip without contacting fingers or forceps to it. |
|
Fast Healing Bandage[35] |
Needleless Microprotrusin Elastoplast System |
Commonly used as a needless patch that infuse medicament along with drug and adhesive matrial. It is most commonly used patch which shows uniform medicament penetration to corneum. |
|
Surgical sutures[36] |
Ethicon Strata fix |
There are numbers of sutures available in market according to the requirement, polyhydroxyacetic ester containing absorble sutures are also available in different dia. Size i.e.0,00,3-0,4-0,5-0(USP Size) etc. Sutures can be one of the following monofilament/from twisted/ braided polyfilaments. Sutures have great handleablility in living tissue. |
|
Surgical staple[37] |
Aeromade Staplers |
Currently a staple becomes specialized instead of sutures in most over surgery as a wound closure and to either remove or connect bowels or lungs parts. |
|
Foam Dressing[33] |
Allevyn |
Foams are more preferable in terms of pain reduction, patient satisfaction and nursing time. It acts as primary wound dressing for insulation and absorption. It consists of breathable top film, highly absorbent foam core and non adherent wound contact layer. |
Table No. 4 Innovative Wound Closure Technology
|
Innovative Wound Closure Technology |
Marketed Product Name |
Remarks |
|
Surgical Closure[38,39] [Patented Product] |
Zip Line Surgical Skin Closure |
It consists of 2 member surgical tape from which one member surgical tape carries anchor to tie strip and second member surgical tape carries releasable locking slide for strip, a tie strip is provided to join the anchor containing tape with another tape to seal the wound. Strip have upper1 toothed surface to provide locking system. |
|
Hemorrhage Control Devices and Methods[40] [PatentedProduct] |
X Stat Syringe |
It consists of applicator with absorbing sponges which is applicable of deep and hemorrhagic wound which effect rapid hemostatic. It stops the high blood flow by absorbing the wound after it gets swell. |
|
Filmated Surgical Gauze[41] [PatentedProduct] |
X Gauze |
Gauze is having great absorptivity hence it is used for the surgical dressing and also in emergency time. |
|
Fibrin Sealant[42,43] [PatentedProduct] |
Evicel |
It is mainly used for bleeding scars, wound and also for cuts. It is applied with the help of spray containing the co2 along with polymers and fibrin. On application it seals the area so that bleeding gets stops rapidly. It also helps in the healing process by covering that area. |
|
Highly Effective Hemostatic Adhesive Gel[44] [PatentedProduct] |
Veti Gel |
Innovative formulation that stops bleeding at the time of application. It immediately sets over the wounds and solidify there to stop the bleeding. Most frequently used in accident and emergency condition. |
|
Incision and Closure Surgical Device[45,46] [PatentedProduct] |
Surgical Zipper Ethizip |
In this device Zipper is fitted to a self adhesive patch which is to be attached on skin surface. Zipper contains contact electrode for electro coagulation. Incision edges get closer when zipper gets interlock by the action of slide. Electrical energy is applied by the electrode when slider drawn the tapes close towards each other. Hence electro coagulation occurs through electrode to the skin and ensures that an edge gets adhered from full depth. |
|
Surgical Glue[47,48] |
Bio Glue Liqui Band Derma Bond |
It is used to stick the edges of the incision by using the formulation like glue. It can be applied by the use of applicator on the edges and with the help of fingers incision are sealed, it hasaffinity to hold the edges of the incision or wound. It is totally painless, needleless and easily applicable. |
|
Wound Closure Shifter[49] |
Top Closure |
It includes shifter and a locking system that locks the shifter at desired location. |
|
Liquefied Sealant[50] |
True Seal |
It is liquefied type of sealant that easily spread due to its liquid state and seals the wound or incision on application. |
4. Images related to innovative wound closure techniques
Fig.1.1.Tegaderm [32,33]
The above image is courtesy of Dr. J.D. Inmam and C.E.Ward. Thanks Dr. J.D. InmamandC.E.Wardfor giving permission to use above images.
Fig.1.2.Allevyn[33]
The above image is courtesy of Joshua S Boateng. Thanks Joshua S Boateng for giving permission to use above images.
Fig.1.3. Steri Strip[34]
The above image is courtesy of Arthur B. Brower. Thanks Arthur B. Brower. for giving permission to use above images.
Fig.1.4. Surgical Sutures[36]
The above image is courtesy of Edward Emil Schmitt. Thanks Edward Emil Schmitt for giving permission to use above images.
Fig.1.5. Surgical Staples [37]
The above image is courtesy of Edward Karl Braun. Thanks Edward Karl Braun for giving permission to use above images.
Fig.2.1.Zipline[38, 39]
The above image is courtesy of Dr.Harrith M. Hasson. Thanks Dr.Harrith M. Hasson for giving permission to use above images.
Fig.2.2. X Stat Syringe[40]
The above image is courtesy of Kenton W. Gregory. Thanks Kenton W. Gregory for giving permission to use above images.
Fig.2.3. X Gauze[41]
The above image is courtesy of Robert W Johnson. Thanks Robert W Johnson for giving permission to use above images.
Fig.2.4. Fibrin Sealant Evicel[42,43]
The above image is courtesy of Peter A. D. Edwardson. Thanks Peter A. D. Edwardson for giving permission to use above images.
Fig.2.5. Veti Gel[44]
The above image is courtesy of Dr.Joseph A. Thanks Dr.Joseph A for giving permission to use above images.
Fig.2.6. Surgical Zipper Tape[45,46]
The above image is courtesy of Pablo Cristian Luchetti. Thanks Pablo Cristian Luchetti for giving permission to use above images.
Fig.2.7. Surgical Glue[47,48]
The above image is courtesy of Galanakis. Thanks Galanakis for giving permission to use above images.
Fig.2.8. Top Closure [49]
Fig.2.9. True Seal [50]
REFERENCE:-
1. David A. Browdie.High strengthbio-compatible tissue adhesive and methods for treating vigorously bleeding surface. Patent-US6310036 B1; Oct. 30,2001.
2. Kiran Sharma, Vijender Singh, Alka Arora.Natural Biodegradable Polymers as Matrices in Transdermal Drug Delivery. International Journal Of Drug Development and Research. 2011; 3(2): 85–103.
3. Hampton T. Breaking Barriers in Transdermal Drug Delivery. JAMA. 2005;293(17); 2083.
4. Rajashri R. Kulkarni, Dipti G. Phadtare. The microneedle patches: an innovative approach. Asian Journal of Pharmacy and Technology. 2015; 5 (4); 195–200.
5. Syeda Ayesha Fathima, Shireen Begum, Syeda Saniya Fatima. Transdermal Drug Delivery System. International Journal of Pharmaceutical and Clinical Research 2017; 9(1); 35–43.
6. P. K. Gaur et al. Transdermal Drug Delivery System: A Review.Asian Journal of Pharmaceutical and Clinical Research. 2009; 2(1); 14‐20.
7. Vandana Yadav et al. Transdermal Drug Delivery: A Technical Writeup. Journal of Pharmaceutical and Scientific Innovation. 2012; 1(1); 5–12.
8. Laurie Swezey. Wound Care Principles: Three Types of Wound Closure. Wound Source. 2011; http://www.woundsource.com/blog/wound-care-principles-three-types-wound-closure
9. Dipen M. Patel, Kavitha K. Formulation and Evaluation Aspects of Transdermal Drug Delivery System. International Journal of Pharmaceutical Sciences Review and Research. 2011; 6(2); 83–90.
10. Kamal Saroha, Bhavna Yadav, Benika Sharma. Transdermal Patch: A Discrete Dosage form. International Journal of Current Pharmaceutical Research. 2011; 3(3); 98–108.
11. A.Srilakshmi et al. Formulation and Evaluation of Transdermal Patches of Irbesartan. Indian Journal of Research in Pharmacy and Biotechnology. 2017; 5(3);212–215.
12. Mithilesh Sahu et al. Medicated Transdermal Therapeutic Systems: An Updated Overview. Research Gate. 2017; 7(1); 43–49.
13. Chensheng Li, Miami, Fla.Composition and Methods for Transdermal Delivery of Acid Labile. Drugs.Patent No.:- US 6024974 A; Feb.15, 2000.
14. Peter Fankhauser, Lotte Schenkel. Transdermal Therapeutic Systems for Active Ingredient Combinations. Patent No.:- US 6024974 A; April 03, 1990.
15. Rishabha Malviya, Pranati Srivastava, G.T. Kulkarni. Applications of Mucilage in Drug Delivery - A Review. Advances in Biological Research. 2011; 5(1); 01–07.
16. Obaidat Rana et al. Enhancement of Levodopa Stability When Complexed With Β-Cyclodextrin in Transdermal Patches. Pharmaceutical Development and Technology. Pub med 2016; 3; 1–12.
17. Yie W. Chien, Te-Yen Chien, Yih-Chain Huang. Transdermal Estrogen/Progestin Dosage Unit, System and Process. Patent No.:- 4906169 mar. 06, 1990.
18. Seaman DS et al. Use of Polytetrafluoroethylene Patch for Temporary Wound Closure after Pediatric Liver Transplantation. National Center for Biotechnology Information. Pub med1996; 62(7); 1034–6.
19. Jong Seob IM. Percutaneous Absorption Preparation Containing Donepezil, and Method for Preparing Same. Patent No.:- US 9622986 B2; Apr.18, 2017.
20. P. Minghetti et al. Development of Local Patches Containing Melilot Extract and Ex Vivo–In Vivo Evaluation of Skin Permeation. European Journal of Pharmaceutical Sciences. 2000; 10 (2); 111–117.
21. Jatav Vijay Singh et al. Design, Formulation and In Vitro Drug Release From Transdermal Patches Containing Nebivolol Hydrochloride as Model Drug. Asian Journal of Pharmacy and Technology.2012; 2 (4); 136–141.
22. Y. Joseph Mo. Transdermal Drug Delivery System Containing Donepezil. Patent No.:- US 9693970 B2; Jul. 04, 2017.
23. Parminder Singh et al.Transdermal Administration of Tamsulosin.Patent No.:-US 9610253 B2; Apr. 04, 2017.
24. Sevgi Gungor, M. Sedef Erdal, Yıldız Ozsoy. Plasticizers in Transdermal Drug Delivery Systems. Recent Advances in Plasticizer. 2012; 92–112.
25. Nigel Crutchley. Bioerodible Patch Comprising a Polyaphron Dispersion. Patent no.:- US 9549896 B2;Jan. 24, 2017.
26. Beny baby et al. Design and evaluation of transdermal patches of propanolol hydrochloride.Research Journal of Pharmacy and Technology. 2009; 2(1); 195–200.
27. Y.J.Cho, H.K. Choi. Enhancement of Percutaneous Absorption of Ketoprofen: Effect of Vehicles and Adhesive Matrix. International Journal of Pharmaceutics. 1998; 169(1); 95–104.
28. Ju Hyun Kim, Young Joo Cho, Hoo Kyun Choi. Effect of Vehicles and Pressure-Sensitive Adhesives onthe Permeation of Tacrine across Hairless Mouseskin.International Journal of Pharmaceutics.2000;196(1); 105–113.
29. S.D. Roy et al. Controlled Transdermal Delivery of Fentanyl: Characterizations of Pressure-Sensitive Adhesives for Matrix Patch Design. Journal of Pharmaceutical Sciences. 1996; 85(5); 491–495.
30. Richa Sachan, Meenakshi Bajpai et al. Transdermal Drug Delivery System: A Review.International Journal of Research and Development in Pharmacy and Life Sciences. 2013; 3(1); 748–765.
31. Pravin Chinchole, Sagar Savale, Kamlesh Wadile. A Novel Approach on Transdermal Drug Delivery System [TDDS].World Journal of Pharmacy and Pharmaceutical Sciences. 2016; 5(4); 932–958.
32. J.D. Inmam and C.E.Ward. Wound Closure Device for Viewing a Wound And Method. Patent No.:-US 5497788 A; Mar. 12, 1996.
33. Joshua S. Boateng et al. Wound Healing Dressing and Drug Delivery System: A Review. Journal of Pharmaceutical Sciences.2008; 97(8); 2892–2923.
34. Arthur B. Brower. Self Adhesive Suture and Bandage. Patent No.:-US 4646731 A; Mar. 03, 1987.
35. Orest Olejnik, Robert T. Lyons, Scott J. Gerondale. Needleless Microprotrusion Elastoplast System. Patent No.:-US 20060100584 A1; May 11, 2006.
36. Edward Emil Schmitt et al. Surgical Sutures. Patent No.:-US 3297033 A;Jan. 10, 1967.
37. Edward Karl Braun, Jurgen Fetzer. Surgical Staples. Patent No.:-US 4505273 A; Mar.19, 1985.
38. Harrith M. Hasson. Surgical Closure. Patent No.:-US 3971384 A; Jul. 27, 1976.
39. Elia de maria. New Skin Closure System Facilitates Wound Healing after Cardiovascular Implantable Electronic Device Surgery. World Journal of Clinical Cases. 2015.
40. Kenton W. Gregory et al. Hemorrhage Control Devices and Methods.Patent No.:-US 8828050 B2; Sept. 09, 2014.
41. Robert W. Johnson. Filmated Surgical Gauze. Patent No.:-US 1701207 A; Feb. 05, 1929.
42. Peter A. D. Edwardson et al. Fibrin Sealant Compositions.Patent No.:-US 5739288 A;Apr. 14, 1998.
43. William d. Spotnitz. Fibrin Sealant: The only Approved Hemostat, Sealant, and Adhesive a Laboratory and Clinical Perspective. International Scholarly Research Notices. 2014; 203943; 28.
44. Joseph A. Landolina , Omar M. Ahmad.Highly Effective Hemostatic Adhesive Polymer Scaffold. Patent No.:-WO 2016209198 A1; Dec. 29, 2016.
45. Pablo Cristian Luchetti. Incision and Closure Surgical Device. Patent No. US 7594914 B2; Sept. 29, 2009.
46. Patrick J. Bastian. A New Form of Noninvasive Wound Closure with a Surgical Zipper. The Journal of Urology. 2003; 169 (5); 1785–1786.
47. Galanakis et al. A Review of Current Hemostatic Agents and Tissue Sealants Used in Laparoscopic Partial Nephrectomy. Review in Urology.2011; 13(3); 131–133.
48. A.S. Jacobsen. Comparing Wound Closure Using Tissue Glue versus Subcuticular Suture for Pediatric Surgical Incisions. Technical Innovation. 14 June 2002.
49. Wound closure shifter available on http://www.topclosure.com-/productprofile.aspx.assessed on 05/08/2017.
50. Liquefied sealant available on http://www.truseal.in/index.php. assessed on 05/08/2017.
Received on 31.08.2017 Modified on 25.09.2017
Accepted on 24.10.2017 © RJPT All right reserved
Research J. Pharm. and Tech 2018; 11(2):805-812.
DOI: 10.5958/0974-360X.2018.00152.X